公开(公告)号：US11883448B2

公开(公告)日：2024-01-30

申请号：US16985459

申请日：2020-08-05

申请人： University of Pittsburgh—Of the Commonwealth System of Higher Education

发明人： Hiroaki Uchida ,  Justus B. Cohen ,  Joseph C. Glorioso, III ,  Paola Grandi

IPC分类号： C12N15/00 ,  A61K35/763 ,  C12N7/00 ,  C07K14/005

CPC分类号： A61K35/763 ,  C07K14/005 ,  C12N7/00 ,  C07K2319/33 ,  C12N2710/16621 ,  C12N2710/16622 ,  C12N2710/16632 ,  C12N2710/16641 ,  C12N2710/16643 ,  C12N2710/16645 ,  C12N2710/16662 ,  C12N2710/16671

摘要： The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.

公开(公告)号：US20170274025A1

公开(公告)日：2017-09-28

申请号：US15616585

申请日：2017-06-07

申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education

发明人： Hiroaki Uchida ,  Justus B. Cohen ,  Joseph C. Glorioso, III ,  Paola Grandi

IPC分类号： A61K35/763 ,  C07K14/005 ,  C12N7/00

CPC分类号： A61K35/763 ,  C07K14/005 ,  C07K2319/33 ,  C12N7/00 ,  C12N2710/16621 ,  C12N2710/16622 ,  C12N2710/16632 ,  C12N2710/16641 ,  C12N2710/16643 ,  C12N2710/16645 ,  C12N2710/16662 ,  C12N2710/16671

摘要： The present invention provides a recombinant herpes simplex virus (HSV), comprising (a) a mutation of the glycoprotein B (gB) at position 285 or 549, (b) a plurality of copies of one or more microRNA target sequences inserted into a locus of an HSV gene required for HSV replication, wherein said target sequence is the reverse complement of microRNA miR-124 and wherein said target sequence is present in the ICP4 gene, and (c) a transgene encoding a matrix metalloproteinase. The present invention also provides a method of killing a cancerous cell using a recombinant HSV according to the invention and a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a recombinant HSV according to the invention.

公开(公告)号：US20180171305A1

公开(公告)日：2018-06-21

申请号：US15849069

申请日：2017-12-20

申请人： Salk Institute for Biological Studies

发明人： Axel Nimmerjahn ,  Charles L. Clark

IPC分类号： C12N7/00 ,  A61P37/06 ,  A61P29/00 ,  C12N15/113 ,  A61K31/713 ,  A61K38/46

CPC分类号： C12N7/00 ,  A61K31/713 ,  A61K38/46 ,  A61K48/0008 ,  A61P29/00 ,  A61P37/06 ,  C12N15/1137 ,  C12N15/86 ,  C12N2310/11 ,  C12N2310/122 ,  C12N2310/14 ,  C12N2310/531 ,  C12N2320/31 ,  C12N2710/10041 ,  C12N2710/10043 ,  C12N2710/10071 ,  C12N2710/10343 ,  C12N2710/16641 ,  C12N2710/16643 ,  C12N2710/16671 ,  C12Y306/00

摘要： The finding that phosphatidylserine (PtdSer) exposure on the outer leaflet of virally transduced cells triggers their engulfment by resident immune cells is described. It is demonstrated that inhibition of phospholipid scramblase 1 (PLSCR1) activity prevents PtdSer externalization and enables prolonged protection of vector-transduced cells from phagocytosis. Methods of inhibiting a virus vector-induced inflammatory response in tissue, methods of prolonging virus vector encoded transgene expression, and methods of modulating an inflammatory response in tissue of a subject, by administering an inhibitor of PLSCR1 are described.

公开(公告)号：US20160250267A1

公开(公告)日：2016-09-01

申请号：US15032958

申请日：2014-10-28

申请人： UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

发明人： Hiroaki UCHIDA ,  Justus B. COHEN ,  Joseph C. GLORIOSO, III ,  Paola GRANDI

IPC分类号： A61K35/763 ,  C12N7/00

CPC分类号： A61K35/763 ,  C07K14/005 ,  C07K2319/33 ,  C12N7/00 ,  C12N2710/16621 ,  C12N2710/16622 ,  C12N2710/16632 ,  C12N2710/16641 ,  C12N2710/16643 ,  C12N2710/16645 ,  C12N2710/16662 ,  C12N2710/16671

摘要： The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.

摘要翻译： 本发明提供了一种重组溶瘤性单纯疱疹病毒（oHSV），其包含对细胞（例如癌细胞）表面上存在的分子（蛋白质，脂质或碳水化合物决定簇）特异的非HSV配体和一种或多种 插入到一个或多个HSV基因座中的一个或多个microRNA靶序列的拷贝，优选在正常（即非癌性）细胞中HSV复制所需的一种或多种HSV基因。 本发明还提供了包含本发明的oHSV的库存和药物组合物以及使用本发明的oHSV杀死肿瘤细胞的方法。

公开(公告)号：US20180057594A1

公开(公告)日：2018-03-01

申请号：US15720696

申请日：2017-09-29

申请人： ONCORUS, INC.

发明人： Luke EVNIN

IPC分类号： C07K16/28 ,  C12N7/00 ,  C07K16/30 ,  C07K14/705 ,  C07K14/725 ,  C12N9/64 ,  A61K35/768

CPC分类号： C07K16/2818 ,  A61K35/76 ,  A61K35/768 ,  A61K2039/507 ,  C07K14/4703 ,  C07K14/522 ,  C07K14/5434 ,  C07K14/5443 ,  C07K14/70503 ,  C07K14/7051 ,  C07K14/70532 ,  C07K14/70596 ,  C07K16/2803 ,  C07K16/2809 ,  C07K16/2827 ,  C07K16/3092 ,  C07K2317/31 ,  C07K2317/76 ,  C07K2319/00 ,  C07K2319/03 ,  C07K2319/30 ,  C12N7/00 ,  C12N9/6491 ,  C12N15/86 ,  C12N2710/16633 ,  C12N2710/16641 ,  C12N2740/16032 ,  C12N2740/16043 ,  C12N2760/20232 ,  C12N2760/20243 ,  Y02A50/466

摘要： Described herein are pseudotyped oncolytic viruses comprising nucleic acids encoding an engager molecule. In some embodiments, the pseudotyped oncolytic viruses comprises nucleic acids encoding an engager molecule and one or more therapeutic molecules. Pharmaceutical compositions containing the pseudotyped oncolytic virus and methods of treating cancer using the pseudotyped oncolytic viruses are further provided herein.

公开(公告)号：US20170035819A1

公开(公告)日：2017-02-09

申请号：US15204350

申请日：2016-07-07

申请人： University of Pittsburgh - Of the Commonwealth System of Higher Education

发明人： Hiroaki Uchida ,  Justus B. Cohen ,  Joseph C. Glorioso, III ,  Paola Grandi

IPC分类号： A61K35/763 ,  C12N7/00

CPC分类号： A61K35/763 ,  C07K14/005 ,  C07K2319/33 ,  C12N7/00 ,  C12N2710/16621 ,  C12N2710/16622 ,  C12N2710/16632 ,  C12N2710/16641 ,  C12N2710/16643 ,  C12N2710/16645 ,  C12N2710/16662 ,  C12N2710/16671

摘要： The present invention provides a recombinant oncolytic Herpes Simplex Virus (oHSV) comprising a non-HSV ligand specific for a molecule (protein, lipid, or carbohydrate determinant) present on the surface of a cell (such as a cancer cell) and one or more copies of one or more microRNA target sequences inserted into one or more HSV gene loci, preferably one or more HSV gene(s) required for replication of HSV in normal (i.e., non-cancerous) cells. The invention further provides stocks and pharmaceutical compositions comprising the inventive oHSV and methods for killing tumor cells employing the inventive oHSV.

摘要翻译： 本发明提供了一种重组溶瘤性单纯疱疹病毒（oHSV），其包含对细胞（例如癌细胞）表面上存在的分子（蛋白质，脂质或碳水化合物决定簇）特异的非HSV配体和一种或多种 插入到一个或多个HSV基因座中的一个或多个microRNA靶序列的拷贝，优选在正常（即非癌性）细胞中HSV复制所需的一种或多种HSV基因。 本发明还提供了包含本发明的oHSV的库存和药物组合物以及使用本发明的oHSV杀死肿瘤细胞的方法。

公开(公告)号：US20150374767A1

公开(公告)日：2015-12-31

申请号：US14768549

申请日：2014-02-21

申请人： VIRTTU BIOLOGICS LIMITED

发明人： Joe CONNER

IPC分类号： A61K35/763 ,  G01N33/50 ,  A61K45/06

CPC分类号： A61K35/763 ,  A61K39/00 ,  A61K45/06 ,  A61K2039/525 ,  C07K14/005 ,  C07K14/52 ,  C07K14/5434 ,  C07K14/70578 ,  C12N2710/16641 ,  C12N2710/16643 ,  C12N2710/16645 ,  C12N2710/16662 ,  C12N2710/16671 ,  G01N33/5011 ,  G01N2500/04 ,  G01N2500/10 ,  A61K2300/00

摘要： A method of treating cancer is disclosed, the method comprising simultaneous or sequential administration of a virus and a receptor tyrosine kinase (RTK) inhibitor.

摘要翻译： 公开了一种治疗癌症的方法，所述方法包括同时或顺序施用病毒和受体酪氨酸激酶（RTK）抑制剂。